Suppr超能文献

宫颈癌治疗中的神经和心脏不良事件:一例术后信迪利单抗诱发的脑炎和心肌炎病例

Neurological and Cardiac Adverse Events in Cervical Cancer Treatment: A Case of Postoperative Sintilimab-Induced Encephalitis and Myocarditis.

作者信息

Guo Haiyu, Wu Huanlei, Li Jun, Li Ruichao

机构信息

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出版信息

Am J Case Rep. 2025 May 26;26:e947730. doi: 10.12659/AJCR.947730.

Abstract

BACKGROUND Immune checkpoint inhibitors (ICIs) have shown considerable promise in enhancing patient outcomes and improving survival rates, offering a new frontier in cancer treatment. As a result, their use in clinical practice has become more widespread. However, the adverse effects associated with ICIs can compromise treatment efficacy. Among these, immune-related neurological adverse events are relatively uncommon, with an incidence rate of approximately 17%. Central nervous system (CNS) symptoms, although less frequent (around 6%), are particularly concerning due to their higher risk compared to peripheral nervous system involvement. Additionally, in recent years, the incidence of cardiac toxicity has been increasing, often indicated by elevated cardiac biomarkers, but most cases are asymptomatic. CASE REPORT This report presents a case of a middle-aged woman with cervical cancer who developed both encephalitis and myocarditis during postoperative consolidation therapy with an immune checkpoint inhibitor. A thorough evaluation, including laboratory tests, imaging studies, and an assessment of the patient's medical history and clinical presentation, excluded infection and paraneoplastic encephalitis as potential causes. She was treated with high-dose corticosteroids and intravenous immunoglobulin (IVIG), resulting in gradual resolution of her central nervous system symptoms and normalization of cardiac biomarkers. CONCLUSIONS Although the incidences of immune-related encephalitis and myocarditis are generally low, they can be very severe. With the increasing use of ICIs in clinical practice, the incidence of immune-related neurological symptoms may rise. This highlights the need for increased vigilance in clinical applications, including early preventive measures and prompt diagnosis and treatment to mitigate the adverse effects of these therapies, thereby maximizing patient benefits.

摘要

背景 免疫检查点抑制剂(ICIs)在改善患者预后和提高生存率方面显示出巨大潜力,为癌症治疗开辟了新领域。因此,它们在临床实践中的应用越来越广泛。然而,与ICIs相关的不良反应可能会影响治疗效果。其中,免疫相关的神经系统不良事件相对少见,发生率约为17%。中枢神经系统(CNS)症状虽然不太常见(约6%),但由于与外周神经系统受累相比风险更高,因而特别值得关注。此外,近年来,心脏毒性的发生率一直在上升,通常表现为心脏生物标志物升高,但大多数病例无症状。病例报告 本报告介绍了一名中年宫颈癌女性患者,在接受免疫检查点抑制剂术后巩固治疗期间发生了脑炎和心肌炎。通过全面评估,包括实验室检查、影像学研究以及对患者病史和临床表现的评估,排除了感染和副肿瘤性脑炎作为潜在病因。她接受了大剂量皮质类固醇和静脉注射免疫球蛋白(IVIG)治疗,中枢神经系统症状逐渐缓解,心脏生物标志物恢复正常。结论 尽管免疫相关脑炎和心肌炎的发生率通常较低,但可能非常严重。随着ICIs在临床实践中的使用增加,免疫相关神经症状的发生率可能会上升。这凸显了在临床应用中提高警惕的必要性,包括早期预防措施以及及时诊断和治疗,以减轻这些治疗的不良反应,从而使患者受益最大化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验